DT02 Rec'd PCTA-10 0 6 JAN 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence (along with any paper referenced as being attached or enclosed) is ng deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450

Rebecca A. Bellas

Print Name of Person Mailing Paper) Signature of Person Mailing Paper

Docket No. ARTHP110US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Applicant:

Hedding-Eckerich

Serial No.:

10/511.026

Filed:

October 8, 2004

For:

USE OF PYRIMIDINE NUCLEOTIDES FOR THE TREATMENT OF AFFECTIONS OF

THE PERIPHERAL NERVOUS SYSTEM

Art Unit: Examiner:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

1. Pursuant to 37 C.F.R. 1.97 and 1.98, and in compliance with 37 C.F.R. 1.56, the Office's attention is directed to the patents, pending applications, publications and other information listed on the attached PTO-1449. A copy of each listed document is enclosed except for: (a) pending applications or (b) those previously cited or submitted to the Office in the following application(s) upon which this application relies for an earlier filing date under 35 U.S.C. 120: or (c) U.S. Patent(s) and published application(s) since the subject application was filed after June 30, 2003.

Serial No.:		
Filing Date:	 	

Regarding any document, publication or other information for which a date is not given on the attached PTO-1449, Applicant(s) believe(s) the same may qualify as "prior" art to this application and should be treated accordingly, although Applicant(s) reserve(s) the right to contest the prior art status of any document, publication or information, should issue arise.

- 2. Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-1449 or a concise explanation of the relevance of the document is set forth in the following document(s):
  - Copy of each English language version of a search report indicating the degree of relevance found by the foreign office of each document being submitted from the search report.

(b)	Attachr	ment entitled "Concise Explanation of Relevance of Non-English Language Documents".			
3. Pu	rsuant t	o 37 C.F.R. 1.97(b) this Statement is being filed (one must be checked):			
(a)	<u>x</u> '	Within 3 months of the filing date or date of entry into the National Stage.			
(b)		Before the mailing date of a first Office Action on the merits. If this Statement is not filed before the mailing date of a first Office Action on the merits, the required certification is given below or, in the absence thereof, the Office is authorized to charge the required fee set forth in 37 C.F.R. 1.17(p) to Deposit Account No. 50-1063 for consideration of this Statement.			
(c)		Before the mailing date of a first Office Action on the merits after a first or second submission after final rejection under 37 C.F.R. 1.129(a).			
(d)		After the period set forth in 37 C.F.R. 1.97(b) but before the mailing date of either a final action or a notice of allowance.			
	(1)	The required certification is given below, or			
	(2)	Enclosed is a check covering the fee set forth in 37 C.F.R. 1.17(p) for consideration of this Statement, or			
	(3)	Charge the fee set forth in 37 C.F.R. 1.17(p) to Deposit Account No. 50-1063			
(e)		After the mailing date of either a final action or a notice of allowance, but before payment of the issue fee. Petition hereby is made for consideration of this Statement and the required certification is indicated below.			
	(1)	Enclosed is a check covering the fee set forth in 37 C.F.R. 1.17(i)(1), or			
	(2)	Charge the fee set forth in 37 C.F.R. 1.17(i)(1) to Deposit Account No. 50-1063.			
4. Ce	rtificatio	on (if applicable)			
(a)		The undersigned hereby certifies that each item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of this Statement.			
(b)	,	The undersigned hereby certifies that no item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the undersigned's knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than 3 months prior to the filing of this Statement.			
		nissioner is hereby authorized to charge any additional fees or credit any overpayment to No. 50-1063.			
		Respectfully Submitted,			
		AMIN & TUROCY, L.L.P.			
1900 Eas Cleveland Telephon	t 9 <sup>th</sup> Str d, OH 4 le: (216				

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
50550101	E 101 101111 144011 10			Application Number	10/511,026
INFORMATION DISCLOSURE			CLOSURE	Filing Date	October 8, 2004
STATEMENT BY APPLICANT		First Named Inventor	Hedding-Eckrich		
<i>**</i> **********************************				Art Unit	
(Use as many sheets as necessary)		Examiner Name			
Sheet	1	of	1	Attorney Docket Number	ARTHP110US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		International Preliminary Examination Report, PCT/DE03/01203, July 19, 2004	
		WATTIG, B., et al. Nucleotides Accelerate Regeneration of Nerves, Zeitschrift Fuer Klinische Medizin (Berlin), Vol. 46, No. 19, 1991, Pages 1371-1373	
		WATTIG, B., et al., Acceleration of Muscle Regeneration by Nucleotide Administration Experimental Morphometric Studies, Zentralblatt Fur Pathologie, Germany 1991, Vol. 137, No. 5, 1991, Pages 409-413	
		WATTIG, B., et al., Acceleration of Nerve and Muscle Regeneration by Administration of Nucleotides - electroneurohphysiological and Morphometrical Investigations, ACTA Histochchemica, Supplementband, Germany 1992, Vol. 42, 1992, Pages 333-339	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.